It is known that COVID-19 has an adverse effect on various organs and systems of the human body. In the available literature, there are isolated reports regarding the development of osteonecrosis after suffering COVID-19. These papers discuss the role of commonly used corticosteroids in the treatment of COVID-19 in the development of osteonecrosis. Our article presents clinical observations of four patients with bilateral osteonecrosis of the femoral heads after treatment with COVID-19. The doses of prednisolone in three patients were 4500 mg, 735 mg and 525 mg. One patient did not receive corticosteroids. Our data showed that osteonecrosis in COVID-19 survivors developed at a shorter time compared to osteonecrosis in patients without coronavirus infection. Two out of four patients had a positive family history (myocardial infarction, hypertension, thrombosis). It is possible that hereditary vascular factors played some role in the genesis of osteonecrosis of the femoral head. Further evidence is needed to understand the development of osteonecrosis after COVID-19. Probably, the development of the disease is synergistically affected by many factors, including steroid and ischemic

Abstract. This retrospective study included 242 of 286 patients who had an appendix ultrasound examination between June 1 and December 31, 2021. The following were reviewed: ultrasound report, pathology report, and clinical records. The pathology report has been used as the gold standard for diagnosing acute appendicitis.

An ultrasound examination (USG) with Doppler mapping was performed in 25 patients with rheumatoid arthritis (RA) and 25 patients with erosive osteoarthritis (EOA) to clarify the ultrasound picture of handjoint damage. We have revealed the characteristic features allowing to perform differential diagnosis between RA and EOA of the hands joints.